NCT06413095: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS |
|
|
| Completed | 1 | 13 | US | Pembrolizumab, Keytruda, MK-3475, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab | Presage Biosciences, Merck Sharp & Dohme LLC | Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma | 06/23 | 06/23 | | |
MK-4830-001, NCT03564691: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 442 | Europe, Canada, Japan, US, RoW | MK-4830, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, Paraplatin, Pemetrexed, ALIMTA®, Pleumet, Pemecad, Lenvatinib, LENVIMA®, Lenvanix, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Cisplatin, Platinol®, Platinol®-AQ, CDDP, MK-4830A | Merck Sharp & Dohme LLC | Neoplasms | 09/25 | 09/25 | | |
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies |
|
|
| Recruiting | 1 | 15 | US | Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475 | Presage Biosciences, Merck Sharp & Dohme LLC | Solid Tumor | 12/31 | 12/31 | | |
